ArticleJAMA network open2026
Mailed Audit and Feedback for Antibiotic Prescribing in Primary Care.
Article in JAMA network open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Importance: Inappropriate antimicrobial use is a major but modifiable contributor to antimicrobial costs and harms. To address this global threat, many countries have implemented national stewardship programs. However, the cost-effectiveness of such programs targeting primary care physicians remains unknown. Objective: To determine the economic value of an antibiotic audit and feedback (A&F) program from a Canadian public payer perspective. Design, Setting, and Participants: This economic evaluation used data from a randomized clinical trial of primary care physicians in Ontario, Canada, in which a mailed A&F intervention reduced antibiotic prescribing among patients 65 years and older. Trial data were linked with administrative databases to estimate the program costs and savings from reduced antibiotic use, adverse events, and undertreatment harms. A decision model was developed to calculate monetary costs and benefits. Data were collected from January 1 to July 1, 2022, and were analyzed from March 1 to April 1, 2025. All costs are reported in 2024 Canadian dollars. Intervention: A mailed A&F letter sent to primary care physicians with their antibiotic prescribing rate compared with their peers, with additional messaging about the harms of unnecessary antibiotics. Main Outcomes and Measures: Net costs and benefits, return on investment (ROI), and probability of achieving a positive ROI (>1). Uncertainty was explored using probabilistic analysis with 5000 simulations and deterministic sensitivity analyses. Results: The study included 4879 primary care physicians, of whom 2711 (55.6%) were male, with a mean (SD) of 25.0 (13.3) years since medical school graduation. The program cost was $5.50 per physician and generated $43.03 in savings. The ROI was $8.82 (95% uncertainty interval, $1.32-$22.56) per dollar invested. The probability that the antibiotic A&F program provided an ROI greater than 1 was 93.2%. Scaling the program to all primary care physicians in Ontario would further improve the estimated ROI. Results were robust across sensitivity analyses. Conclusions and Relevance: In this economic evaluation of a mailed antibiotic A&F intervention, the intervention was associated with substantial economic and clinical value. These findings support A&F as a scalable, low-cost component of antimicrobial stewardship programs and highlight its potential to optimize prescribing and reduce antimicrobial resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.